5 Key Takeaways
-
1
A clinic-based AI algorithm reduced screen failures in geographic atrophy (GA) trial prescreening.
-
2
The AI tool showed close agreement with manual measurements of GA lesion area.
-
3
In a study of 107 eyes, AI identified 80 eligible and 27 ineligible for trials.
-
4
The screen failure rate was 16% with AI, compared to 25% using standard workflows.
-
5
AI tools may enhance trial efficiency and reduce the burden on patients and investigators.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.